Evaluation of the significance of isolated tumor cells in gynecological cancers.

In gynecological oncology, sentinel lymph node biopsy with ultrastaging is increasingly used in cervical, endometrial and vulvar cancers. Isolated tumor cells (ITCs) are encountered much more commonly in this scenario than when standard histologic evaluation of non-sentinel lymph nodes is performed. The prognostic implication of ITCs in gynecological cancers is not well defined and international guidelines do not offer clear guidance regarding the management of gynecological cancers with ITCs.

Practical recommendations for the use of PARP inhibitors in the treatment of ovarian cancer.

Background: There is no doubt that PARP inhibitors (PARPi) have significantly improved the prognosis of patients with advanced-stage ovarian cancer. In the history of treatment for this disease, their impact is second only to the introduction of platinum-based chemotherapy. As with any new therapeutic modality, integrating PARPi into routine clinical practice is a complex process.

ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025.

In 2023, based on advances in the understanding of the pathological and molecular features of endometrial carcinoma, an updated International Federation of Gynaecology and Obstetrics (FIGO) staging system was published, aiming to better define prognostic groups and identify relevant treatment subgroups by including factors reflecting tumour biology (histological subtypes, lymphovascular space invasion, and molecular classification) alongside refinements of anatomical factors (peritoneal carcinomatosis and lymph node metastasis). As part of its mission to improve the quality of care for people with gynaecological cancers, the European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) updated the ESGO-ESTRO-ESP evidence-based guidelines published in 2021 by incorporating this revised FIGO staging and the large body of new evidence addressing the management of endometrial carcinoma. The development process of these guidelines was based on a systematic literature review and critical appraisal process involving an international multidisciplinary development group consisting of 30 experts from relevant disciplines (gynaecological oncology, radiation oncology, medical oncology, and pathology).

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without Mutation.

Purpose: Patients with platinum-resistant/platinum-refractory high-grade serous ovarian cancer (HGSOC) without a mutation have poor prognosis and limited treatment options. We report efficacy and biomarker data from EPIK-O, which investigated alpelisib + olaparib versus single-agent chemotherapy in these patients.

Patients And Methods: EPIK-O was an open-label, phase III trial that randomly assigned patients with platinum-resistant/platinum-refractory HGSOC with no germline or known somatic mutation 1:1 to alpelisib 200 mg once daily + olaparib 200 mg twice daily or treatment of physician's choice (TPC; paclitaxel 80 mg/m once weekly or pegylated liposomal doxorubicin 40-50 mg/m once every 28 days).

Sentinel lymph node biopsy without systematic pelvic lymphadenectomy in females with early-stage cervical cancer: final outcome of the SENTIX prospective, single-arm, noninferiority, international trial.

Sentinel lymph node (SLN) biopsy with ultrastaging is standard in endometrial and vulvar cancers, whereas systematic pelvic lymphadenectomy (PLND) remains recommended in cervical cancer. The SENTIX trial prospectively evaluated the safety of SLN biopsy without PLND in early-stage cervical cancer. Female patients, International Federation of Gynaecology and Obstetrics 2018 stage IA1/LVSI+ to IB2 disease, were enrolled between 2016 and 2020 across 47 sites in 18 countries.